Int. Journal of Clinical Pharmacology and Therapeutics, Volume 47 - February (96 - 103)

A PK/PD approach on the effects of clarithromycin against oral and nasal microbiota of healthy volunteers
A.P. Del Bortolo Ruenis1, G.C. Nobre Franco2, S. Baglie6, R.H. Lopes Motta3, R.P. Simões1, P.L. Rosalen1, L.M. Franco4, R.A. Moreno5, E. Abib Jr.5, F.C. Groppo1
1 Piracicaba Dental School, State University of Campinas (UNICAMP), Piracicaba, 2 University of Taubaté (UNITAU), Taubaté, 3 Department of Physiological Sciences, São Leopoldo Dentistry School, Campinas, 4 Faculty of Health Sciences, Methodist University of Piracicaba, Piracicaba, 5 Synchrophar Assessoria e Desenvolvimento de Projetos Clínicos, Campinas, SP, 6 Department of Pharmaceutical Sciences, Ponta Grossa State University, Ponta Grossa, PR, Brazil

Add to Cart  

 

DOI 10.5414/CPP47096

Abstract

Objective: To assess the pharmacokinetics of clarithromycin (CLR) and its effects on oral and nasal microbiota in healthy volunteers in an open, randomized, two-period crossover design. Methods: A single 500 mg oral dose of CLR (Group 1: Merck; Group 2: Klaricid) was administered observing a 1-week interval between doses. Blood samples were collected from pre-dose to 24 h. Plasmatic concentrations of CLR were quantified by the LC-MS-MS method. Saliva and nasal mucosa swabs were obtained previously and after 1.33, 2, 6 and 12 h of drug administration. Pharmacokinetics and PK/PD (t > MIC, %t > MIC and AUC0-24/MIC ratio) parameters were estimated. The microorganism counts were obtained on different culture media. Results: No statistically significant differences were observed between the two formulations (p > 0.05) regarding the pharmacokinetic parameters. Total microorganisms, staphylococci and streptococci counts did not show statistical differences (p > 0.05) between the two groups during each sampling time. Considering the microorganisms of each group, no statistically significant differences were found after drug administration, but all differed from pre-dose counts (p < 0.05). The observed t > MIC ranged from 14.45 h (± 1.69) to 1.19 h (± 2.17) considering MICs of 0.25 µg/ml and 2.0 µg/ml, respectively. There was no correlation between any t > MIC, %t > MIC or AUC0-24 and bacterial reduction (between 0- and 12-h periods). However, the profile of reduction of microorganisms in both saliva and nasal samples were compatible with high values of t > MIC verified for both clarithromycin formulations. Conclusion: Both formulations of clarithromycin had similar pharmacokinetics and efficacy.

Author Details

Authors

Departments

  • 1 Piracicaba Dental School, State University of Campinas (UNICAMP), Piracicaba,
  • 2 University of Taubaté (UNITAU), Taubaté,
  • 3 Department of Physiological Sciences, São Leopoldo Dentistry School, Campinas,
  • 4 Faculty of Health Sciences, Methodist University of Piracicaba, Piracicaba,
  • 5 Synchrophar Assessoria e Desenvolvimento de Projetos Clínicos, Campinas, SP,
  • 6 Department of Pharmaceutical Sciences, Ponta Grossa State University, Ponta Grossa, PR, Brazil

Address

Prof. Dr. F.C. Groppo; Piracicaba Dental School, State University of Campinas (UNICAMP), Av. Limeira 901, ZIP 13414-903, Piracicaba, SP, Brazil
Email: [email protected]

Citation

A.P. Del Bortolo Ruenis, G.C. Nobre Franco, S. Baglie, R.H. Lopes Motta, R.P. Simões, P.L. Rosalen, L.M. Franco, R.A. Moreno, E. Abib Jr. and F.C. Groppo .A PK/PD approach on the effects of clarithromycin against oral and nasal microbiota of healthy volunteers . 2009; 47: 96-103. doi: 10.5414/CPP47096.

###article_not_exists_msg###

Shopping Overview

Shopping Overview
Type Qtty Discount VAT Price
Your basket is empty
View Cart